SCHWARZ PHARMA AG / Release of an announcement according to Article 37x of the WpHG [the German Securities Trading Act] 31.10.2008 Interim report according to Article 37x of the WpHG ---------------------------------------------------------------------------<pre></pre> 3 31 October 20081 October 2008 SCHSCHWARZ PHARMA presents Nine Months ReportWARZ PHARMA presents Nine Months Report The sales trend of the SCHWARZ PHARMA group in the first 9 months of 2008 was in line with our expectations and improved year-on-year1. The best performing products were Prostavasin(R) (alprostadil), including Edex(R) (alprostadil), followed by Atmadisc(R) (fluticasone/salmeterol) and Neupro(R) (rotigotine transdermal patch) as additional key sales drivers. All three products recorded year-on-year sales growth. The operating result of the SCHWARZ PHARMA group in the first 9 months was consistent with our expectations. The group's financial result improved considerably year-on-year. Within the scope of integration into the UCB group, SCHWARZ PHARMA granted an interest-bearing vendor loan, generating interest income in the first 9 months which was distinctly higher than that recorded in the previous year. The net result was also in line with our expectations. August saw the start of the UCB group's SHAPE program, focusing UCB's biopharma activities on its core areas CNS (Central Nervous System) and immunology disorders. The program includes reductions of the company's global workforce. In October, a compensation agreement and socially equitable arrangements for employees affected by the global restructuring measures were agreed with the works councils in Germany. In September, marketing approval for Vimpat(R) (lacosamide), a drug for treating epilepsy in ad-on therapy, was received for the European market. Vimpat(R) was successfully launched in Germany in the same month. As part of the process of integrating SCHWARZ PHARMA AG into the UCB group, 13 affiliated companies ceased to belong to the company's scope of consolidation as per end of fiscal year 2007. All details on the prior year period only relate to continued business operations. A cold chain for Neupro(R) (rotigotine transdermal patch) was successfully implemented throughout Europe in September 2008, guaranteeing a sufficient supply to current Parkinson's patients. SCHWARZ PHARMA expects to be in a position to make Neupro(R) available to newly diagnosed patients in the first half of 2009. The German market launch of Neupro(R) for treating Restless Legs Syndrome (RLS) is also planned for the first six months of 2009. In July 2008, SCHWARZ PHARMA AG met the demand of the Federal Financial Supervisory Authority (BaFin) to publish the reporting error the latter had determined in fiscal year 2005. The correction will be carried out within the scope of the annual consolidated financial statements for 2008. SCHWARZ PHARMA has meanwhile withdrawn the objection lodged against the opinion of the BaFin and the error it determined. Out Outlook for 2008 unchangedlook for 2008 unchanged SCHWARZ PHARMA expects revenues to stay level at around EUR350 million in fiscal year 2008, with a negative net result in the higher double-digit million ranges. This outlook takes into account the impact of the inability to deliver Neupro(R) in the U.S., announced in March 2008, and possible measures for restoring delivery capability as well as start-up expenses for producing the drug fesoterodine. This outlook does not include earnings from the divestment of products or partnerships. Likewise not included are expenses possibly arising from following instructions given under the terms of the domination and profit transfer agreement. SCHWARZ PHARMA AG (seated in Monheim, Germany) is a member of the UCB group, Brussels/Belgium (www.ucb-group.com). UCB is listed on the Euronext exchange in Brussels and holds around 89% of all SCHWARZ PHARMA shares. UCB (Brussels, Belgium) (www.ucb-group.com/) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative medicines with focus on the fields of central nervous system and immunology. Employing around 12,000 people in over 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on Euronext Brussels. Contact: Sylvia Heitzer,Tel: +49 2173 48 1238; Antje Witte, Tel.: +32 2 559 9414 Internet: www.schwarzpharma.com This press release contains assumptions, expectations, and forecasts on future sector trends, on future legal and commercial developments, and on the future development of the company. These assumptions, expectations, and forecasts are no guarantee for future performance and are subject to change at any time. Consequently, future reports and the factual circumstances of the company may deviate materially from the outlook presented by the above. The company assumes no responsibility for updating such assumptions, expectations, and forecasts on future sector trends, on future legal and commercial developments, and on the future development of the company. DGAP 31.10.2008 --------------------------------------------------------------------------- Language: English Issuer: SCHWARZ PHARMA AG Alfred-Nobel-Str. 10 40789 Monheim Deutschland Internet: www.schwarzpharma.com End of News DGAP News-Service ---------------------------------------------------------------------------
DGAP-IRE: SCHWARZ PHARMA AG: SCHWARZ PHARMA presents Nine Months Report
| Source: EQS Group AG